Findings on alcohol dependence point to promising avenues for targeted therapies.
Kuehn
Bridget M
BM
D000437:Alcoholism / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D000818:Animals; D001552:Benzazepines / Q000627:therapeutic use; D006801:Humans; D009271:Naltrexone / Q000627:therapeutic use; D009292:Narcotic Antagonists / Q000627:therapeutic use; D064729:Neurokinin-1 Receptor Antagonists; D018722:Nicotinic Agonists / Q000627:therapeutic use; D010597:Pharmacogenetics; D011725:Pyridines / Q000627:therapeutic use; D011810:Quinoxalines / Q000627:therapeutic use; D018019:Receptors, Corticotropin-Releasing Hormone / Q000037:antagonists & inhibitors; D017450:Receptors, Opioid, mu / Q000235:genetics; D013315:Stress, Psychological / Q000378:metabolism; D014230:Triazoles / Q000627:therapeutic use; D000068580:Varenicline; D000099052:CRF Receptor, Type 1
D001552:Benzazepines; C527551:LY686017; D009292:Narcotic Antagonists; D064729:Neurokinin-1 Receptor Antagonists; D018722:Nicotinic Agonists; C485764:OPRM1 protein, human; D011725:Pyridines; D011810:Quinoxalines; D018019:Receptors, Corticotropin-Releasing Hormone; D017450:Receptors, Opioid, mu; D014230:Triazoles; D000099052:CRF Receptor, Type 1; D009271:Naltrexone; D000068580:Varenicline